We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.92B
AUM Growth
-$82.3M
Cap. Flow
-$215M
Cap. Flow %
-11.22%
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
2
ABT icon
Abbott
ABT
+$10.5M
3
OTLK icon
Outlook Therapeutics
OTLK
+$7.71M
4
BPTH
Bio-Path Holdings Inc
BPTH
+$7.56M
5
SHPG
Shire pic
SHPG
+$5.34M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$22.6M
2
BIIB icon
Biogen
BIIB
+$7.14M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$3.88M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.22M
5
ESRX
Express Scripts Holding Company
ESRX
+$2.84M

Sector Composition

Rank Sector Weight
1 Healthcare 12.85%
2 Industrials 0.12%
3 Consumer Staples 0.07%
4 Consumer Discretionary 0.06%
5 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXMD icon
326
TherapeuticsMD
TXMD
$23.8M
– –
-2,608
Closed -$1.07M
TXMD icon
327
PUT
TherapeuticsMD
TXMD
$23.8M
– –
-8
Closed -$259K
UTHR icon
328
CALL
United Therapeutics
UTHR
$26.1B
– –
-750
Closed -$8.36M
VRTX icon
329
Vertex Pharmaceuticals
VRTX
$124B
– –
-23,320
Closed -$2.02M
CMRX
330
DELISTED
Chimerix, Inc.
CMRX
– –
-53,620
Closed -$274K
EGRX
331
CALL
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-1,000
Closed -$4.05M
EGRX
332
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-10,000
Closed -$405K
EGRX
333
PUT
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-100
Closed -$405K
ASXC
334
CALL
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-455
Closed -$2.51M
ASXC
335
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-37
Closed -$205K
SCPX
336
DELISTED
Scorpius Holdings, Inc.
SCPX
– –
-3
Closed -$626K
TTOO
337
DELISTED
T2 Biosystems, Inc
TTOO
– –
-29
Closed -$1.43M
CBAY
338
DELISTED
Cymabay Therapeutics
CBAY
– –
-67,534
Closed -$91K
ICPT
339
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-72
Closed -$925K
MTEM
340
DELISTED
Molecular Templates, Inc.
MTEM
– –
-5,078
Closed -$385K
BLCM
341
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-7,702
Closed -$720K
APEN
342
DELISTED
Apollo Endosurgery, Inc.
APEN
– –
-14,375
Closed -$206K
ALBO
343
DELISTED
Albireo Pharma Inc
ALBO
– –
-11,917
Closed -$118K
OTIC
344
DELISTED
Otonomy, Inc.
OTIC
– –
-50,000
Closed -$746K
RDUS
345
DELISTED
Radius Health, Inc.
RDUS
– –
-65,000
Closed -$2.3M
ATRS
346
CALL
DELISTED
Antares Pharma, Inc.
ATRS
– –
-399
Closed -$35K
ADXS
347
CALL
DELISTED
Advaxis Inc
ADXS
– –
-155
Closed -$2.1M
XLRN
348
DELISTED
Acceleron Pharma
XLRN
– –
-50,000
Closed -$1.32M
TRIL
349
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-14,137
Closed -$131K
ALXN
350
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-27,856
Closed -$3.88M
12 13
14
15 16

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $215M in Q2 2016, closing 99 positions and reducing 80 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Abbott worth $10.4M.

  • Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
  • Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
  • Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
  • Sabby Management opened 94 new positions and closed 99 in Q2 2016.
  • Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.